Edition:
India

Grifols SA (GIKLY.PK)

GIKLY.PK on OTC Markets Group

15.80USD
5 Sep 2019
Change (% chg)

-- (--)
Prev Close
$15.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,307
52-wk High
$16.21
52-wk Low
$12.60

Latest Key Developments (Source: Significant Developments)

Grifols Signs Technology Collaboration Agreement With Mondragon
Friday, 6 Sep 2019 

Sept 6 (Reuters) - Grifols SA ::SIGNS AGREEMENT WITH MONDRAGON TO JOINTLY DEVELOP HEALTHCARE SECTOR-RELATED AUTOMATION.  Full Article

Grifols H1 Net Profit Down At 286.9 Mln Euros YoY
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Grifols SA ::H1 NET PROFIT 286.9 MILLION EUROS VERSUS 319.0 MILLION EUROS YEAR AGO.H1 NET REVENUE 2.42 BILLION EUROS VERSUS 2.12 BILLION EUROS YEAR AGO.H1 ADJUSTED NET PROFIT 352.1 MILLION EUROS VERSUS 355.9 MILLION EUROS YEAR AGO.H1 RESEARCH AND DEVELOPMENT NET INVESTMENT 167.7 MILLION EUROS VERSUS 141.3 MILLION EUROS YEAR AGO.TO ALLOCATE 1.40 BILLION EUROS TO CAPITAL INVESTMENTS FROM 2018 TO 2022.  Full Article

Grifols Announces FDA Approval Of Xembify, 20% Subcutaneous Immunoglobulin For Primary Immunodeficiencies
Thursday, 4 Jul 2019 

July 4 (Reuters) - Grifols SA ::GRIFOLS ANNOUNCES FDA APPROVAL OF XEMBIFY®, 20% SUBCUTANEOUS IMMUNOGLOBULIN FOR PRIMARY IMMUNODEFICIENCIES.  Full Article

Grifols Says FDA Approves Xembify In US
Thursday, 4 Jul 2019 

July 4 (Reuters) - Grifols SA ::SAYS US FOOD AND DRUG ADMINISTRATION (FDA) APPROVES GRIFOLS' NEW 20% SUBCUTANEOUS IMMUNOGLOBULIN PRODUCT XEMBIFY USED TO TREAT PRIMARY IMMUNODEFICIENCIES.PLANS TO LAUNCH XEMBIFY IN U.S. DURING LAST QUARTER OF 2019 AND IS WORKING TO OBTAIN APPROVAL IN CANADA, EUROPE AND OTHER MARKETS.  Full Article

Grifols Selected As Main Supplier For A New Manufacturing Plant In Northern Africa
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Grifols SA ::SELECTED BY SOLUDIA MAGHREB AS MAIN SUPPLIER FOR A NEW MANUFACTURING PLANT IN NORTHERN AFRICA.TO DEVELOP, BUILD AND AUTOMATE MAIN PROCESS EQUIPMENT FOR THE IV SOLUTIONS LINE.  Full Article

Grifols To Launch Plasma-Protein-Based Bleeding-Control Solutions
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Grifols SA ::TO LAUNCH PLASMA-PROTEIN-BASED BLEEDING-CONTROL SOLUTIONS.GLOBAL LAUNCH, EXPECTED IN SECOND HALF 2019, WILL BE FOLLOWED BY OTHER PRODUCTS.  Full Article

Grifols To Pay Dividend, Reaffirms 1.40 Bln Euros In Capital Investments
Friday, 24 May 2019 

May 24 (Reuters) - Grifols SA ::SAYS TO PAY NET DIVIDEND OF 0.008 EUROS/CLASS B SHARE ON JUNE 11.TO PAY ORDINARY NET DIVIDEND OF 0.118 EUROS PER SHARE ON JUNE 11.REAFFIRMS ITS LONG-TERM SUSTAINABLE GROWTH STRATEGY WITH 1.40 BILLION EUROS IN CAPITAL INVESTMENTS IN 2018-2022.  Full Article

Grifols Q1 Net Profit Down At 114.4 Mln Euros YoY
Tuesday, 7 May 2019 

May 7 (Reuters) - Grifols SA ::Q1 NET PROFIT 114.4 MILLION EUROS VERSUS 143.4 MILLION EUROS YEAR AGO.Q1 EBITDA 305.6 MILLION EUROS VERSUS 297.4 MILLION EUROS YEAR AGO.Q1 NET SALES 1.16 BILLION EUROS VERSUS 1.02 BILLION EUROS YEAR AGO.Q1 RESEARCH AND DEVELOPMENT NET INVESTMENT 89.3 MILLION EUROS VERSUS 73.5 MILLION EUROS YEAR AGO.Q1 ADJUSTED NET PROFIT 148.2 MILLION EUROS VERSUS 160.8 MILLION EUROS YEAR AGO.  Full Article

Grifols Exercises Call Option Over 51 Pct Of IBBI For USD 100 Mln
Thursday, 2 May 2019 

May 2 (Reuters) - Grifols SA ::EXERCISES CALL OPTION OVER 51 PERCENT OF INTERSTATE BLOOD BANK, INC. (IBBI).SAYS PURCHASE PRICE OF USD 100 MILLION.ON APRIL 8, 2016 GRIFOLS ACQUIRED 49 PERCENT OF IBBI .  Full Article

Grifols Receives FDA Approval Of Erytra Eflexis
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Grifols SA ::GRIFOLS RECEIVES FDA APPROVAL OF ERYTRA EFLEXIS®, THE LATEST ADVANCEMENT IN SCALABLE BLOOD TYPING SOLUTIONS.  Full Article

No consensus analysis data available.